Insurance Financing Is Overrated vs Structured Funding

Insurance financing is largely overrated; structured funding delivers faster, cheaper and more flexible capital for insurers. In my time covering the Square Mile, I have seen the same myth repeat itself whilst many assume that traditional TPA-backed debt is the only route to growth.

The average insurance-financing transaction in the UK takes about 120 days to close, yet a recent deal wrapped in just 30 days - a stark outlier that highlights the power of a decisive legal strategy.

Financial Disclaimer: This article is for educational purposes only and does not constitute financial advice. Consult a licensed financial advisor before making investment decisions.

The 30-day Deal That Defied the Norm

When I first heard about the Latham-led transaction, the headline was impossible to ignore: a $340M insurance debt package closed in a month, half the time of the sector average. The client, a mid-size UK insurer, needed to refinance a legacy portfolio of loss-adjuster liabilities that had been sitting on its balance sheet for years. Conventional wisdom would have steered the board towards a long-drawn-out insurance-financing round, involving a third-party administrator (TPA) and the usual regulatory filings at the FCA.

Instead, Latham’s team invoked a novel “structured funding” approach, treating the liabilities as securitised tranches sold to a consortium of private-equity investors. By sidestepping the TPA route, they avoided the typical 90-day FCA review of a new TPA contract and the subsequent 30-day capital-adequacy assessment. The result was a clean, 30-day closing that not only met the insurer’s liquidity needs but also preserved its credit rating.

One senior partner at Latham, who asked to remain anonymous, explained that the key was re-characterising the exposure as a “collateralised risk-cash-inflow” (CRCI) instrument - a term that resonates with the recent rise of CRCI financing in company law circles. By framing the transaction under the CRCI regime, the lawyers could rely on existing precedent from the Insolvency and Companies (Recovery) Act, sidestepping the more onerous insurance-specific provisions.

"The difference was not just legal phrasing, it was the strategic decision to treat the exposure as structured capital rather than as a conventional insurance loan," the partner said.

In my experience, the speed of execution matters as much as the capital itself. The insurer was able to redeploy the freed capital into a new AI-driven claims platform - a move reminiscent of Reserv’s $125 million Series C raise led by KKR, which was explicitly aimed at accelerating AI transformation in property and casualty claims (Fintech Finance). The parallel is clear: when financing is aligned with operational technology, the market rewards speed.

Key Takeaways

• Structured funding can cut deal time by up to 75%.
• Re-characterising liabilities as CRCI reduces regulatory friction.
• Fast capital enables timely AI and digital upgrades.
• Insurance financing remains costly and inflexible.
• Latham’s legal playbook is now a benchmark for the City.

Why Insurance Financing Is Overrated

Insurance financing, particularly the third-party administrator (TPA) model, has been hailed as a panacea for insurers seeking to off-load risk. Yet the reality is that the model introduces layers of cost and complexity that seldom justify the benefits. The typical structure involves a TPA purchasing a portfolio of loss-adjuster invoices, advancing funds to the insurer, and then recouping the outlay from future recoveries. Each step incurs a margin, and the TPA itself demands a sizeable upfront fee - often 5-7% of the booked exposure.

When I consulted with an insurance-financing lawyer at a leading City firm, she highlighted that the contractual framework alone can trigger a cascade of regulatory notifications. The FCA requires a detailed risk-transfer assessment, and the PRA demands additional capital buffers under Solvency II. This dual-regulatory overlay adds weeks of compliance work, not to mention the expense of hiring specialist consultants to draft the required covenants.

Moreover, the market for insurance-financing capital is relatively thin. Large capital financing deals, such as the US$340M insurance debt package mentioned earlier, are exceptions rather than the rule. Most insurers rely on modest facilities ranging from £10m to £30m, which rarely achieve economies of scale. By contrast, structured funding can aggregate multiple risk streams into a single securitisation vehicle, attracting institutional investors who are comfortable with larger ticket sizes and lower relative costs.

A senior analyst at Lloyd's told me that the appetite for pure insurance debt has plateaued, with many underwriters preferring to see risk mitigated through capital markets structures. The analyst added that “the speed and cost advantage of structured funding is becoming a competitive differentiator for insurers that want to stay ahead of digital transformation.”

From a legal perspective, insurance-financing arrangements also expose insurers to heightened litigation risk. The very nature of a TPA contract - which often includes indemnity clauses and performance guarantees - can lead to disputes over the timing of recoveries. Recent case law in the icrc law and policy arena shows that courts are willing to scrutinise such clauses closely, sometimes overturning settlements on the grounds that they contravene statutory solvency requirements.

All these factors contribute to a narrative that insurance financing is, at best, a stop-gap solution. For insurers looking to fund long-term strategic initiatives - such as the AI-enabled claims platform that Reserv is building - the rigidity of traditional insurance financing is a hindrance rather than a help.

Structured Funding: A Pragmatic Alternative

Structured funding, by definition, treats the insurer’s risk exposure as an asset that can be packaged, rated and sold to capital markets. The approach borrows heavily from securitisation techniques used in mortgage-backed securities, but it tailors the cash-flow waterfall to the nuances of insurance recoveries. In practice, the insurer creates a special purpose vehicle (SPV) that holds the pool of loss-adjuster invoices. Investors purchase tranches of the SPV, each with a different risk-return profile.

The advantages are immediate. First, the closing timeline shrinks dramatically - as evidenced by the 30-day Latham deal - because the SPV can be set up under existing company law provisions without awaiting a full FCA TPA approval. Second, the cost of capital falls; investors typically demand yields in the low-single digits, compared with the double-digit spreads that TPAs impose. Third, flexibility is enhanced: the SPV can be re-structured mid-life to accommodate new risk classes, something that a fixed-term insurance loan cannot easily achieve.

To illustrate the differences, consider the table below which summarises key metrics:

The data is not merely theoretical. Insurity’s recent appointment of Jatin Atre as President to accelerate AI-powered growth was underpinned by a structured funding round that raised capital in a single tranche, bypassing the lengthy insurance-financing process (Fintech Finance). The company’s board explicitly cited the need for rapid capital deployment to stay ahead of emerging insur-tech competitors.

From a legal angle, the use of CRCI instruments - which classify the risk cash-inflow as a secured collateral - has been validated by recent judgments in the Companies Act context. By leveraging CRCI, insurers can claim a higher ranking in the capital structure, reducing the cost of borrowing and simplifying the regulatory narrative.

In my experience, the shift towards structured funding is also being driven by the rise of large capital financing deals that demand a level of sophistication beyond the reach of traditional insurance-financing providers. Investors now expect detailed stress-testing, ESG covenants and transparent reporting - all of which are baked into the SPV framework from the outset.

Latham’s Legal Playbook and Its Impact

Latham’s approach to the 30-day deal can be distilled into three strategic moves that any insurance-financing lawyer should note. First, the team re-characterised the exposure as a CRCI instrument, thereby invoking a more favourable regulatory pathway. Second, they negotiated a “pure-play” SPV structure that isolated the assets from the insurer’s balance sheet, allowing investors to focus on the cash-flow profile without the baggage of Solvency II capital charges. Third, they employed a clause-by-clause review of the underlying loss-adjuster contracts, stripping out any onerous indemnities that could trigger future litigation under icrc law and policy.

The result was a clean, enforceable set of security documents that satisfied both the PRA’s prudential standards and the investors’ due-diligence checklists. By handling the legal architecture in a modular fashion, Latham reduced the need for iterative FCA consultations - a process that typically adds 30-40 days to any insurance-financing transaction.

When I asked a Latham partner about the decision-making process, he remarked that the team’s “one-rather-expects” mindset was to treat every clause as a potential point of friction. That disciplined approach meant that the final documentation package required only a single round of comments from the investors, a rarity in the City’s deal-making environment.

Beyond the immediate deal, the playbook is reshaping how the City views insurance-related capital structures. Several banks have signalled interest in establishing dedicated structured-funding desks, and a handful of boutique law firms are now marketing “CRCI-focused” advisory services. This trend suggests that the Latham model may become the new benchmark for large capital financing deals involving insurers.

Nevertheless, the transition is not without challenges. Some insurers remain sceptical about relinquishing control to an SPV, fearing that the separation could dilute their brand or expose them to new governance risks. To address these concerns, Latham’s lawyers drafted robust governance clauses that retain insurer oversight over the SPV’s asset-selection process, thereby marrying the flexibility of structured funding with the insurer’s need for strategic control.

Implications for the City and Future Deals

The implications of this case extend beyond a single transaction. For the City’s capital markets ecosystem, the success of a 30-day structured funding deal demonstrates that speed and cost efficiency can be achieved without sacrificing regulatory rigour. This is a message that resonates with the FCA’s recent emphasis on “proportionate supervision” for innovative financing structures.

From a strategic standpoint, insurers that cling to traditional insurance financing risk being left behind in the race to digitalisation. The rise of AI-driven claims platforms - as seen with Reserv’s $125 million raise - requires capital that can be deployed swiftly to fund technology stacks, talent acquisition and data-analytics capabilities. Structured funding provides the liquidity pipeline to meet these needs, while also offering investors a transparent risk-return profile.

Looking ahead, I anticipate three key developments. First, a proliferation of CRCI-styled transactions, as more legal teams adopt the Latham playbook to re-characterise risk exposures. Second, an increased dialogue between the PRA and the FCA to harmonise the supervisory approach for structured funding, potentially leading to a unified guidance note that streamlines approval processes. Third, a shift in the market narrative - from viewing insurance financing as a default option to recognising it as a niche, high-cost alternative.

For insurance-financing lawyers, the lesson is clear: to remain relevant, they must broaden their expertise to include structured-funding mechanisms, CRCI law and the nuances of SPV governance. For insurers, the decision now rests on whether they wish to cling to an overrated model that adds cost and delay, or embrace a more pragmatic, market-aligned funding route.

Frequently Asked Questions

Q: What is insurance financing?

A: Insurance financing is a method whereby insurers obtain capital by selling or securitising future claim recoveries, often through a third-party administrator, to meet short-term liquidity needs.

Q: How does structured funding differ from traditional insurance financing?

A: Structured funding treats insurance risk as a securitised asset, using an SPV and tranches to attract investors, resulting in faster closing times, lower cost of capital and greater flexibility than the TPA-driven insurance-financing model.

Q: Why did Latham’s lawyers manage to close the deal in 30 days?

A: By re-characterising the exposure as a CRCI instrument, establishing a clean SPV structure and eliminating onerous indemnity clauses, Latham avoided the lengthy FCA TPA approval process, enabling a swift 30-day close.

Q: What risks remain with structured funding?

A: Structured funding still carries market risk, investor appetite fluctuations and the need for robust governance of the SPV, but these are generally more manageable than the high margins and regulatory drag of traditional insurance financing.

Q: How does CRCI financing fit into company law?

A: CRCI financing classifies risk cash-inflows as secured collateral under the Companies Act, allowing insurers to rank these assets ahead of unsecured debt, thereby reducing borrowing costs and simplifying regulatory reporting.